Authors
Latest:
The Developing Role of Anti–Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal CancerAnti-EGFR therapy is a valuable addition to the armamentarium of treatment options for patients with metastatic colorectal cancer. However, RAS mutation status is an imperfect biomarker for prediction of therapeutic outcomes in this setting. The recent discovery of tumor sidedness as a predictor of response highlights how little we understand about which patients are the most appropriate to receive drugs that target EGFR.
Latest:
Radical Prostatectomy for Patients With Oligometastatic Prostate CancerIn this review, we will examine the theories supporting treatment to achieve local disease control in oligometastatic prostate cancer, analyze the evidence supporting cytoreductive prostatectomy, and review selected relevant ongoing clinical trials.
Latest:
Radical Prostatectomy for Patients With Oligometastatic Prostate CancerIn this review, we will examine the theories supporting treatment to achieve local disease control in oligometastatic prostate cancer, analyze the evidence supporting cytoreductive prostatectomy, and review selected relevant ongoing clinical trials.
Latest:
Radical Prostatectomy for Patients With Oligometastatic Prostate CancerIn this review, we will examine the theories supporting treatment to achieve local disease control in oligometastatic prostate cancer, analyze the evidence supporting cytoreductive prostatectomy, and review selected relevant ongoing clinical trials.
Latest:
Strategies for Addressing Cancer Patients’ Complaints of FatigueCancer-related fatigue is a common, albeit complex, symptom experienced by many cancer patients. Identification of fatigue and assessment of its severity should be a part of routine office care and can be performed using simple, one-question screening tools.
Latest:
Strategies for Addressing Cancer Patients’ Complaints of FatigueCancer-related fatigue is a common, albeit complex, symptom experienced by many cancer patients. Identification of fatigue and assessment of its severity should be a part of routine office care and can be performed using simple, one-question screening tools.
Latest:
ADCs May Preserve Responses in Later Lines of Ovarian Cancer TherapyAntibody-drug conjugates like Rina-S may be able to salvage some of the responses that are often lost in the later lines of treatment, according to Elizabeth Lee, MD.
Latest:
PI3K Inhibitors: Understanding Toxicity Mechanisms and ManagementHere, we briefly describe the clinical efficacy of PI3K inhibitors, then discuss the mechanisms and management of the more common unusual toxicities seen with these agents.
Latest:
Unmet Needs in Diffuse Large B-Cell LymphomaAndre H. Goy, MD, and Andrew Ip, MD, offer closing remarks on unmet needs in the treatment of diffuse large B-cell lymphoma.
Latest:
POINT-Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy?Quality of life is better after modern radiotherapy compared with surgery.
Latest:
Breast Lesion in Patient With HIVA 41-year-old woman with a past medical history notable for HIV underwent her first screening mammogram, which demonstrated a 1.5-cm irregular focal asymmetry in the left breast. What is your diagnosis?
Latest:
Hypofractionated Regimen Safe, Feasible in Elderly Bladder Cancer PatientsIn this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.
Latest:
ctDNA Predicts Outcomes in Lung Cancer Patients Receiving Radiation TherapyThis peer-to-peer exchange highlights results of a study that tested whether analyzing circulating tumor DNA (ctDNA) during treatment with chemoradiotherapy could predict outcomes in patients with localized lung cancer.
Latest:
ctDNA Predicts Outcomes in Lung Cancer Patients Receiving Radiation TherapyThis peer-to-peer exchange highlights results of a study that tested whether analyzing circulating tumor DNA (ctDNA) during treatment with chemoradiotherapy could predict outcomes in patients with localized lung cancer.
Latest:
Endings & Beginnings-Grief, Loss, and Letting GoAs an oncology health care provider, it is crucially important to process grief and loss in order to best care for yourself and your patients.
Latest:
Risk of AML in Thyroid Cancer Patients Treated With Radioactive IodineIn this interview we discuss a study that examined the risk of acute myeloid leukemia in thyroid cancer patients who have been treated with surgery and radioiodine therapy vs those treated with surgery alone.
Latest:
ColoScape Assay Can Detect Recurrence in Colorectal Cancer PatientsIn this interview, we discuss an assay that can detect disease recurrence in colorectal cancer patients.
Latest:
Clinical Decision Making in Surveillance of Non–Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular MarkersIn this article, we discuss the requirements for development and validation of urine markers and the factors that hamper their clinical implementation. We also review current surveillance guidelines for NMIBC and provide an overview of approved urine markers for the detection and surveillance of NMIBC.
Latest:
Clinical Decision Making in Surveillance of Non–Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular MarkersIn this article, we discuss the requirements for development and validation of urine markers and the factors that hamper their clinical implementation. We also review current surveillance guidelines for NMIBC and provide an overview of approved urine markers for the detection and surveillance of NMIBC.
Latest:
SIO President Lynda Balneaves Hopes to Continue Work on Expanding the Society’s ReachIn this interview we discuss the goals of SIO, the response to donations intended for interdisciplinary integrative health, and how palliative care and psychosocial oncology can enhance each other.
Latest:
Emergence of a Novel Staging System for Oropharyngeal Squamous Cell Carcinoma Based on HPV StatusThe staging of oropharyngeal squamous cell carcinoma has undergone key changes in the eighth edition of the American Joint Committee on Cancer Staging Manual, set to take effect January 1, 2018. We describe the revised staging parameters and the rationale in support of the changes.
Latest:
Emergence of a Novel Staging System for Oropharyngeal Squamous Cell Carcinoma Based on HPV StatusThe staging of oropharyngeal squamous cell carcinoma has undergone key changes in the eighth edition of the American Joint Committee on Cancer Staging Manual, set to take effect January 1, 2018. We describe the revised staging parameters and the rationale in support of the changes.
Latest:
Emergence of a Novel Staging System for Oropharyngeal Squamous Cell Carcinoma Based on HPV StatusThe staging of oropharyngeal squamous cell carcinoma has undergone key changes in the eighth edition of the American Joint Committee on Cancer Staging Manual, set to take effect January 1, 2018. We describe the revised staging parameters and the rationale in support of the changes.
Latest:
Revolutionizing Oncodermatology Techniques and Managing Adverse EffectsScalp cooling may enhance patients’ quality of life when managing hair loss associated with cancer treatment.
Latest:
Radiation Dermatitis: Recognition, Prevention, and ManagementThis article highlights the typical skin reactions associated with RT, as well as current evidence-based approaches to management and intervention.
Latest:
Deciding the Duration of Adjuvant Chemotherapy in a Patient With Stage III Colon Cancer: When Can Less Be More?A previously healthy 36-year-old man initially presented to his primary care physician with occasional bloody stools and dull right upper quadrant pain. Blood was sometimes mixed into his stools but was more often seen on the toilet paper after wiping.
Latest:
Optimizing Treatment Approaches in Advanced Renal CancerThis article provides a practical perspective on the management of advanced RCC, as well as insight into the current models of risk stratification and ongoing clinical trials. The discussion will focus on the currently available systemic therapies; other strategies that are beyond the scope of this article include active surveillance and metastasectomy.
Latest:
Future of Non–Clear Cell Renal Cell CarcinomaPanelists discuss the rapidly evolving landscape of non–clear cell renal cell carcinoma, emphasizing the shift toward subtype-specific clinical trials, the critical role of next-generation sequencing and germline testing in guiding personalized treatment, and the importance of ongoing research collaborations to advance precision medicine and improve patient outcomes.
Latest:
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing OutcomesIn those with DLBCL, Burkitt lymphoma, and Hodgkin lymphoma, cure is often achieved. Furthermore, in the salvage setting, whether auto-HCT or allo-HCT is used, the same appears to be true. A great deal of progress has been made in the treatment of lymphoma in patients with HIV infection, but more remains to be done before outcomes are comparable to those of the general population.
Latest:
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing OutcomesIn those with DLBCL, Burkitt lymphoma, and Hodgkin lymphoma, cure is often achieved. Furthermore, in the salvage setting, whether auto-HCT or allo-HCT is used, the same appears to be true. A great deal of progress has been made in the treatment of lymphoma in patients with HIV infection, but more remains to be done before outcomes are comparable to those of the general population.
